SEEQC UK Awarded ÂŁ6.8M Innovate UK Grant to Build Enterprise-Level Quantum Enhanced Computer for Pharmaceutical R&D
The partnership will accelerate the use of quantum computing within pharmaceutical research to dramatically reduce the time required for drug development on a global scale benefitting from working with the UKâ€™s National Quantum Computing Centre (NQCC), also in the consortium.
Breakthroughs in Pharmaceutical Benchmarking and Simulation
This program is focused on developing high-value simulation tools to support photodynamic therapies for cancer treatment. Today, useful simulations of photosensitising drugs are not possible with classical computing power alone. SEEQCâ€™s project will develop an application-specific quantum computer designed to simulate the most classically challenging tasks within this research.
â€śToday, drug discovery is a labour and time-intensive iterative process with immense costs. Thanks to our world-leading partners and the invaluable commercial benchmarking by our end-customers at Merck, we have the opportunity to develop a quantum computing platform that can radically improve the efficiency of drug development,â€ť said Matthew Hutchings, co-founder and CPO at SEEQC.
â€śWe see this project as a major milestone in the commercialization of quantum computing for meaningful enterprise applications like pharmaceutical development. I'm encouraged by the fact that so many global firms are willing and able to collaborate to further the advancement of quantum technology and provide real-world value to businesses,â€ť said John Levy, co-founder and CEO of SEEQC.
SEEQC leads a consortium of quantum computing partners for the ISCF QuPharma project including Riverlane, Oxford Instruments, the University of Oxford, Medicines Discovery Catapult, and members from the Science and Technology Facilities Council, including the UKâ€™s National Quantum Computing Centre. The custom nature of the project required close development to build several bespoke components and enable tight integration.
SEEQCâ€™s project marks the first time a quantum computer has been integrated with a high-performance computer in the same network infrastructure. SEEQCâ€™s is the worldâ€™s first true high-performance quantum computer integration at the enterprise level and will require the development of a custom cryostat with unique capabilities. The quantum computer will require a redesigned refrigerator to support cooling at multiple levels, specifically for the cryogenic decoder.
A Specifically Designed, Scalable Quantum Computer
In the next 18 months, SEEQCâ€™s quantum computer will perform a quantum simulation designed to support core elements of this use case on its full-stack platform and demonstrate a clear route to commercial scalability towards simulations of drugs for photodynamic cancer therapies. Merck will benchmark the performance of this application-specific machine and determine its commercial viability to support its global R&D efforts.
â€śWe are excited to work with our partners in the consortium to create tangible value with the implementation of quantum computing technology in drug development. The application-specific development of a scalable quantum computer has the potential to disrupt virtual drug discovery approaches and we are looking forward to being an early adaptor,â€ť said Philipp Harbach, head of in silico research at Merck.
Additional Innovate UK Grant Wins
SEEQCâ€™s UK team was awarded two additional grants from Innovate UKâ€™s ÂŁ36M ISCF project funding round that will develop key components that support the project.
The first of the two projects, a ÂŁ6.8 million initiative led by Riverlane, will develop advanced quantum calibration methods that utilise machine learning and support the integration of SEEQCâ€™s unique superconducting classical logic platform with cryoCMOS components to support deep memory.
The second project, a ÂŁ6.5 million initiative led by sureCore, will also support the integration of SEEQCâ€™s unique superconducting classical logic platform with cryoCMOS components, combining the optimal features of each component in support of the companyâ€™s platform development.
Combined, these projects awarded SEEQC and its partners a total of over ÂŁ20M from Innovate UKâ€™s Commercialising Quantum Technologies: CRD & Tech round 2 funding.
SEEQC is developing the first fully digital quantum computing platform for global businesses. SEEQC combines classical and quantum technologies to address the efficiency, stability and cost issues endemic to quantum computing systems. The company applies classical and quantum technology through digital readout and control technology and a unique chip-scale architecture. SEEQCâ€™s quantum system provides the energy- and cost-efficiency, speed and digital control required to make quantum computing useful and bring the first commercially-scalable, problem-specific quantum computing applications to market.
The company is one of the first companies to have built a superconductor multi-layer commercial chip foundry and through this experience has the infrastructure in place for design, testing and manufacturing of quantum-ready superconductors. SEEQC is a spin-out of HYPRES, the worldâ€™s leading developer of superconductor electronics. SEEQCâ€™s team of executives and scientists have deep expertise and experience in commercial superconductive computing solutions and quantum computing. SEEQC is based in Elmsford, NY with facilities in London, UK and Naples, Italy.
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of peopleâ€™s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices â€“ the company is everywhere. In 2020, Merck generated sales of â‚¬ 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merckâ€™s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.